Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Sara Lonardi, Fotios Loupakis et al.|The Lancet Oncology|2020Cited by 322
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)Carmine De Angelis, Grazia Arpino, Martina Pagliuca et al.|The Oncologist|2025Cited by 0